In our previous report, c-MET expression was enhanced in the doxorubicin-resistant ovarian cancer cells, which affected BCRP levels via PI3K/AKT activation, suggesting a novel link between c-MET and BCRP-mediated resistance [35]. The gene discussed is AKT1; the disease is ovarian cancer.